N-3 polyunsaturated fatty acids do not influence the efficacy of dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention

Abstract

Background: We aimed to prospectively assess the influence of the recommended dose, 1.0 g of polyunsaturated fatty acids (N-3 PUFA) daily, on platelet reactivity in patients with stable angina pectoris (SAP) after elective percutaneous coronary intervention (PCI). Methods: Forty consecutive patients with SAP and successful PCI were randomized to the study group (group PUFA: n = 20; age 65 ± 8; standard therapy + 75 mgacetylsalicylic acid + 75 mg clopidogrel + N-3 PUFA/Omacor 1 g daily) and the control group (group C: n = 20; age 65 ± 9; standard therapy + 75 mg acetylsalicylic acid + 75 mg clopidogrel). Platelet reactivity tests (COL, TRAP ASPI, ADP) were performed using whole blood aggregometry (multiplate platelet [PIT] function analysis) on the 2nd and 30th day after PCI. Results: Baseline patients' characteristics and clinical outcomes were comparable between the groups. There were no differences between both groups in the mean values of the PTL tests measured 30 days after PCI (PUFA vs. C: ASPI: 18.5 ± 17 vs. 27 ±29 U, COL: 30.4 ± 14.3 vs. 30.3 ± 13.4 U, ADP:25.4 ± 16.1 vs. 20 ± 10.7 U, TRAP: 65.8 ± 25.6vs. 57.1 ± 20.4 U, p = NS). The mean delta values of the PTL tests (18-24 h post-PCI/30 days post-PCI) were also comparable between the groups. The PTL aggregometry results were related to time-the baseline values of the ADP (p = 0.003), COL (p = 0.037) and TRAP (p < 0.001) tests were smaller and the ASPI (p = 0.027) test was higher than those measured after 1-month. Conclusions: N-3 PUFA supplementation does not affect the efficacy of dual antiplatelet therapy in patients with SAP after PCI. © 2013 Via Medica.